Treatment of sickle cell anemia crises with fructose-1,6-diphosphate as an analgesic drug
US6312707A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2000 |
| Grant date | Nov 6, 2001 |
| Priority date | — |
| Expiry date | Jun 12, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Fructose-1,6-diphosphate (FDP) has been shown, in double-blinded controlled clinical trials on patients with sickle cell anemia, to substantially reduce the pain suffered by such patients during the recurrent ischemic crises that are caused by red blood cell sickling. Tests on patients who have been hospitalized for such crises demonstrated that when they received an intravenous injection of FDP, they reported substantially lower pain levels during their hospital stays than control groups that received identical treatment without any FDP. Apparently, FDP has never previously been used or even tested in human clinical trials, to treat sickle cell anemia. In addition, FDP has never previously been reported to have any analgesic (pain-reducing) activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.